APOB and familial hypercholesterolemia: TKM-ApoB is a systemically-delivered RNAi therapeutic based on SNALP carrying an siRNA against the ApoB (Apolipoprotein B) mRNA in order to downregulate the protein which facilitates the uptake of LDL into various cell types and tissues, reducing the LDL cholesterol levels in hypercholesterolemia patients.